Health and Healthcare

Merck : MRK

All Merck Articles

1087 Articles

Chris Lange | Mar 27, 2019 at 8:50 AM EDT

Major Pharma Sees a Few Wild Swings in Short Interest

The March 15 short interest data have been compared with the previous figures, and short interest in most of these…

Jon C. Ogg | Mar 25, 2019 at 12:10 PM EDT

The 10 Companies Buying Back the Most Stock

Stock buybacks have come under more scrutiny by the public and politicians in recent years, but companies still aggressively are…

Jon C. Ogg | Mar 22, 2019 at 1:45 PM EDT

As Recession Fears Grow, 15 Stocks to Survive a Stock Market Correction

During times of uncertainty and fear, many investors have to look for a place to hide when they know that…

Chris Lange | Mar 12, 2019 at 8:35 AM EDT

Big Pharma Short Interest Backs Off, With One Huge Exception

The February 28 short interest data have been compared with the previous figures, and short interest in most of these…

Lee Jackson | Mar 1, 2019 at 7:30 AM EST

5 Safe Merrill Lynch US 1 List Stocks to Buy That Pay Big Dividends

These five outstanding ideas from Merrill Lynch are decidedly more conservative. Given their strong and consistent dividends, they offer investors…

Chris Lange | Feb 28, 2019 at 8:30 AM EST

Major Pharma Sees Tremendous Rise in Short Interest

The February 15 short interest data have been compared with the previous figures, and short interest in most of these…

Jon C. Ogg | Feb 22, 2019 at 8:52 AM EST

Top Analyst Upgrades and Downgrades: Biogen, Broadcom, Citigroup, Equifax, Fitbit, Intel, Kraft Heinz, Merck, Roku, Under Armour, UTC, Zillow and More

The top analyst upgrades, downgrades and initiations seen on Friday included Biogen, Broadcom, Citigroup, Equifax, Fitbit, Intel, Kraft Heinz, Merck,…

Chris Lange | Feb 21, 2019 at 9:55 AM EST

Is Merck Overpaying for Immune Design?

Immune Design shares absolutely exploded on Thursday after Merck announced that it would be acquiring the firm at what some…

Jon C. Ogg | Feb 20, 2019 at 8:45 AM EST

Top Analyst Upgrades and Downgrades: CenturyLink, Deere, Ecolab, E*Trade, Merck, Southwest Air, S&P, Transocean, Walmart and More

The top analyst upgrades, downgrades and initiations seen on Wednesday included CenturyLink, Deere, Ecolab, E*Trade, Merck, Southwest Airlines, S&P, Transocean…

Chris Lange | Feb 12, 2019 at 9:35 AM EST

Major Pharma Scares Off Short Sellers

The January 31 short interest data have been compared with the previous figures, and short interest in most of these…

Jon C. Ogg | Feb 11, 2019 at 7:10 AM EST

The 15 Best Dividend Stocks for Retirees to Own

There are many stocks that are targeted toward mature adults and seniors or that offer classical investing themes for those…

Lee Jackson | Feb 7, 2019 at 7:25 AM EST

Merrill Lynch Adds Top Large Cap Pharmaceutical Leader to US 1 List

A new addition to the Merrill Lynch US 1 list, plus four additional stocks that offer a fair degree of…

Chris Lange | Feb 1, 2019 at 8:35 AM EST

Merck Clears a Low Hurdle for Q4 Earnings

Merck released better-than-expected fourth-quarter financial results after the markets closed on Thursday.

Chris Lange | Jan 31, 2019 at 11:15 AM EST

What to Expect When Merck Reports on Friday

Merck is scheduled to release its fourth-quarter before the markets open on Friday, and analysts are looking for solid top…

Chris Lange | Jan 28, 2019 at 10:10 AM EST

Short Interest Spikes in a Couple Major Pharma Stocks

The January 15 short interest data have been compared with the previous figures, and short interest moves in these selected…

1 … 17 18 19 20 21 … 73

Merck : MRK

All Merck Articles

Major Pharma Sees a Few Wild Swings in Short Interest

The 10 Companies Buying Back the Most Stock

As Recession Fears Grow, 15 Stocks to Survive a Stock Market Correction

Big Pharma Short Interest Backs Off, With One Huge Exception

5 Safe Merrill Lynch US 1 List Stocks to Buy That Pay Big Dividends

Major Pharma Sees Tremendous Rise in Short Interest

Top Analyst Upgrades and Downgrades: Biogen, Broadcom, Citigroup, Equifax, Fitbit, Intel, Kraft Heinz, Merck, Roku, Under Armour, UTC, Zillow and More

Is Merck Overpaying for Immune Design?

Top Analyst Upgrades and Downgrades: CenturyLink, Deere, Ecolab, E*Trade, Merck, Southwest Air, S&P, Transocean, Walmart and More

Major Pharma Scares Off Short Sellers

The 15 Best Dividend Stocks for Retirees to Own

Merrill Lynch Adds Top Large Cap Pharmaceutical Leader to US 1 List

Merck Clears a Low Hurdle for Q4 Earnings

What to Expect When Merck Reports on Friday

Short Interest Spikes in a Couple Major Pharma Stocks

XOP vs. OIH: Do Drillers or Service Providers Best Ride Crude Above $100?

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

America’s Debt Just Crossed a Level It Hasn’t Hit Since 1946, and Households Are Next in Line

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

America's Debt Just Crossed a Level It Hasn't Hit Since 1946, and Households Are Next in Line

XOP vs. OIH: Do Drillers or Service Providers Best Ride Crude Above $100?

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

Merck : MRK

All Merck Articles

Major Pharma Sees a Few Wild Swings in Short Interest

The 10 Companies Buying Back the Most Stock

As Recession Fears Grow, 15 Stocks to Survive a Stock Market Correction

Big Pharma Short Interest Backs Off, With One Huge Exception

5 Safe Merrill Lynch US 1 List Stocks to Buy That Pay Big Dividends

Major Pharma Sees Tremendous Rise in Short Interest

Top Analyst Upgrades and Downgrades: Biogen, Broadcom, Citigroup, Equifax, Fitbit, Intel, Kraft Heinz, Merck, Roku, Under Armour, UTC, Zillow and More

Is Merck Overpaying for Immune Design?

Top Analyst Upgrades and Downgrades: CenturyLink, Deere, Ecolab, E*Trade, Merck, Southwest Air, S&P, Transocean, Walmart and More

Major Pharma Scares Off Short Sellers

The 15 Best Dividend Stocks for Retirees to Own

Merrill Lynch Adds Top Large Cap Pharmaceutical Leader to US 1 List

Merck Clears a Low Hurdle for Q4 Earnings

What to Expect When Merck Reports on Friday

Short Interest Spikes in a Couple Major Pharma Stocks

XOP vs. OIH: Do Drillers or Service Providers Best Ride Crude Above $100?

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

America’s Debt Just Crossed a Level It Hasn’t Hit Since 1946, and Households Are Next in Line

Featured Reads

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

America's Debt Just Crossed a Level It Hasn't Hit Since 1946, and Households Are Next in Line